Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 AUROBINDO PHARMA   ACTAVIS
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-23
ACTAVIS
Dec-18
AUROBINDO PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs71516,037-   
Low Rs39710,758-   
Sales per share (Unadj.) Rs424.23,933.9-  
Earnings per share (Unadj.) Rs32.9-1,267.1-  
Cash flow per share (Unadj.) Rs54.1414.5-  
Dividends per share (Unadj.) Rs3.000-  
Avg Dividend yield %0.50-  
Book value per share (Unadj.) Rs458.116,225.6-  
Shares outstanding (eoy) m585.94332.60-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x1.33.4 38.5%   
Avg P/E ratio x16.9-10.6 -159.8%  
P/CF ratio (eoy) x10.332.3 31.8%  
Price / Book Value ratio x1.20.8 147.0%  
Dividend payout %9.10-   
Avg Mkt Cap Rs m325,7534,456,026 7.3%   
No. of employees `000NA16.9 0.0%   
Total wages/salary Rs m35,2230-   
Avg. sales/employee Rs Th077,421.7-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0-24,937.6-  
INCOME DATA
Net Sales Rs m248,5541,308,427 19.0%  
Other income Rs m2,90625,021 11.6%   
Total revenues Rs m251,4601,333,448 18.9%   
Gross profit Rs m37,07034,287 108.1%  
Depreciation Rs m12,446559,324 2.2%   
Interest Rs m1,40575,504 1.9%   
Profit before tax Rs m26,125-575,519 -4.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0146,780 0.0%   
Tax Rs m6,849-7,293 -93.9%   
Profit after tax Rs m19,277-421,445 -4.6%  
Gross profit margin %14.92.6 569.1%  
Effective tax rate %26.21.3 2,068.6%   
Net profit margin %7.8-32.2 -24.1%  
BALANCE SHEET DATA
Current assets Rs m214,599536,648 40.0%   
Current liabilities Rs m114,938474,737 24.2%   
Net working cap to sales %40.14.7 847.4%  
Current ratio x1.91.1 165.2%  
Inventory Days Days2120 105.3%  
Debtors Days Days6666 98.9%  
Net fixed assets Rs m176,668148,107 119.3%   
Share capital Rs m5860-   
"Free" reserves Rs m267,8130-   
Net worth Rs m268,3995,396,648 5.0%   
Long term debt Rs m6,1901,900,356 0.3%   
Total assets Rs m392,1258,436,189 4.6%  
Interest coverage x19.6-6.6 -295.9%   
Debt to equity ratio x00.4 6.5%  
Sales to assets ratio x0.60.2 408.7%   
Return on assets %5.3-4.1 -128.6%  
Return on equity %7.2-7.8 -92.0%  
Return on capital %10.0-4.8 -207.1%  
Exports to sales %33.70-   
Imports to sales %15.30-   
Net fx Rs m44,0360-   
CASH FLOW
From Operations Rs m23,868467,451 5.1%  
From Investments Rs m-39,778256,804 -15.5%  
From Financial Activity Rs m18,144-802,287 -2.3%  
Net Cashflow Rs m2,298-77,642 -3.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 82.88 Rs / USD

Compare AUROBINDO PHARMA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare AUROBINDO PHARMA With: AARTI DRUGS  VIVO BIO TECH  PARNAX LAB  UNJHA FORMUL  BAFNA PHARMA  



Today's Market

Sensex Today Trades Lower | Metal & PSB Stocks Shine | TCS, Apollo Tyre Drop 3% Sensex Today Trades Lower | Metal & PSB Stocks Shine | TCS, Apollo Tyre Drop 3%(10:30 am)

Asian shares slipped before a Bank of Japan policy decision where authorities are likely to bring an end to the world's last negative rates regime.